TY - JOUR
T1 - ARIA (Allergic Rhinitis and its Impact on Asthma) 2019. Percorsi di cura per la rinite allergica – ITALIA
AU - Passalacqua, Giovanni
AU - Cecchi, Lorenzo
AU - Canonica, Giorgio Walter
AU - Lombardi, Carlo
AU - Ventura, Maria Teresa
AU - Bachert, Claus
AU - Fokkens, Wystke J.
AU - Haahtela, Tari
AU - Klimek, Ludger
AU - Papadopoulos, Nikos G.
AU - Pfaar, Oliver
AU - Valiulis, Arunas
AU - Onorato, Gabrielle L.
AU - Czarlewski, Wienczyslawa
AU - Bedbrook, Anna
AU - Bousquet Per Conto del Gruppo Aria-Italia, Jean
N1 - Funding Information: Conflitto di interessi: T. Haahtela ha ricevuto compensi da: GSK, Mundipharma, Orion Pharma e Sanofi. L. Klimek ha ricevuto fondi e compensi da: Allergopharma, MEDA/Mylan, HAL Allergie, ALK Abelló, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT biotech, Lofarma, Allergy Therapeut., AstraZeneca, GSK, Inmunotk, Cassella med; è membro di: AeDA, DGHNO, Deutsche Akademie für Aller-gologie und klinische Immunologie, HNO-BV, GPA, EAACI. N.G. Papadopoulos ha ricevuto compensi e fondi da: Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare. O. Pfaar ha ricevuto fondi e compensi da: ALK-Abelló, Allergopharma, Staller-genes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis S.A., Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, m Glaxo Smith Kline, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi- Aventis e Sanofi-Genzyme, Med Update Europe GmbH, streame-dup! GmbH, Pohl-Boskamp, Inmunotek S.L., John Wiley and Sons, AS, Paul-Martini-Stiftung (PMS). J. Bousquet ha ricevuto compensi da: Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, KYomed-Innov, Purina. Gli altri autori dichiarano l’assenza di conflitto di interessi. Publisher Copyright: © 2021 Il Pensiero Scientifico Editore s.r.l.. All rights reserved. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021/7/1
Y1 - 2021/7/1
N2 - Allergic rhinitis and asthma represent global health problems for all age groups. ARIA (Allergic Rhinitis and its Impact on Asthma) project was initiated during a WHO workshop in 1999 In its 2010 and 2017 Revisions, ARIA has developed clinical practice guidelines for the management of allergic rhinitis and asthma co-morbidities based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation). The 2019 Revision embedded real-life data into the GRADE recommendations to develop next-generation guidelines. Care pathways for allergen immunotherapy proposed a multi-sectoral approach. This paper reviews these two recent documents adding the impact of ARIA in Italy.
AB - Allergic rhinitis and asthma represent global health problems for all age groups. ARIA (Allergic Rhinitis and its Impact on Asthma) project was initiated during a WHO workshop in 1999 In its 2010 and 2017 Revisions, ARIA has developed clinical practice guidelines for the management of allergic rhinitis and asthma co-morbidities based on GRADE (Grading of Recommendation, Assessment, Development and Evaluation). The 2019 Revision embedded real-life data into the GRADE recommendations to develop next-generation guidelines. Care pathways for allergen immunotherapy proposed a multi-sectoral approach. This paper reviews these two recent documents adding the impact of ARIA in Italy.
KW - ARIA
KW - Allergic rhinitis
KW - App
KW - Digital technology
KW - Guidelines
KW - Pharmacological therapy
KW - Specific immunotherapy
UR - http://www.scopus.com/inward/record.url?scp=85111739075&partnerID=8YFLogxK
U2 - https://doi.org/10.1701/3638.36187
DO - https://doi.org/10.1701/3638.36187
M3 - Article
C2 - 34263879
SN - 2038-1840
VL - 112
SP - 516
EP - 528
JO - Recenti progressi in medicina
JF - Recenti progressi in medicina
IS - 7
ER -